MedTrace Logo

Antiplatelet Therapy in Chronic Urticaria

NCT06268470 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-02-21

No results posted yet for this study

Summary

This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria

Conditions

  • Chronic Urticaria

Interventions

DRUG

Desloratadine plus cilostazol and dipyridamole

Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day

DRUG

Desloratadine

Desloratadine 20 mg/day

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Jettanong Klaewsongkram, MD · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2024-03-01
Completion
2024-05-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06268470 on ClinicalTrials.gov